Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is an open label, single-arm, Phase I study to evaluate the efficacy and safety of
allogenic natural killer(NK) cells in subjects with refractory or relapsed AML after
allogeneic hematopoietic stem cell transplantation(allo-HSCT). A leukapheresis procedure will
be performed to manufacture NK cells. Prior to allogenic NK cells infusion subjects will
receive chemotherapy with azacitidine.